This research study is a Phase II clinical trial, which tests the safety and effectiveness of
an investigational drug to learn whether the drug works in treating a specific cancer.
"Investigational" means that the drug is being studied and that research doctors are trying
to find out more about it-such as the safest dose to use, the side effects it may cause and
if the drug is effective for treating your type of cancer. It also means that the FDA has not
yet approved the drug for your type of cancer or for any use outside of research studies.
It has been found that some people with NSCLC have a change (mutation) in a certain gene
called the ALK gene. This mutated gene helps cancer cells grow. There is a drug (crizotinib)
that has been approved by the FDA for the treatment of people with NSCLC who have mutations
in the ALK gene. Most people respond to crizotinib initially. Over time, however, patients
may stop responding (become resistant) to crizotinib because of additional changes in the ALK
gene that makes crizotinib ineffective.
AUY922 is an investigational drug that may stop cancer cells from growing abnormally. This
drug has been used in other research studies. Information from those other research studies
suggests that AUY922 may be effective in killing cancer cells that have become resistant to
drugs like crizotinib. Only participants with changes in the ALK gene will be allowed to
participate in this study.
The purpose of this study is to test the safety of AUY922 and determine how well AUY922
treats participants with advanced, ALK-positive NSCLC.